Abstract 166P
Background
Schwann cells (SCs) are a type of peripheral nerve system(PNS) glial cell that support the viability of myelinated and unmyelinated peripheral nerve fibers. Our previous studies identified SCs in human lung cancer specimens and demonstrated that SCs could increase the metastasis of lung cancer by activating the PI3K/AKT/GSK-3b/Snail-7wist signaling pathway and enhancing M2 macrophage polarization via CCL2 secretion. However, in the lung cancer mouse model, complete identification of airway nerves (or other cellular/subcellular objects) has not been possible due to patchy distribution and micron-scale size.
Methods
In this study, we describe a method using tissue clearing to acquire the first complete image of three-dimensional (3D) innervation in lung cancer. Mouse airways were harvested from the Metastatic tumor model of C57BI/6 mice and separated from the heart. The tissues were dehydrated, rehydrated and completely transparented. The specimens were labeled for the pan-neuronal marker PGP9.5 with a mouse antibody. All images were acquired using a confocal microscope. 3D images of fluorescently casted airways were processed to make airway masks. To quantify visceral pleural nerve distribution in mice, nerves were modeled using computer tractography and measured in different lung cancer regions.
Results
We found that nerves are widely distributed in both lung and lung tissues. The shape of peripheral nerves is similar to blood vessels, showing reticular shape along the bronchi and bronchioles. However, the distribution of peripheral nerves in the lung has not changed due to lung cancer. Interestingly and critically, the fluorescence intensity of the nerve near the side of lung cancer is much stronger, suggesting that the phenotype of peripheral nerves may change after interaction with lung cancer cells. The nerve growth in lung cancer tissue is abundant and active.
Conclusions
We first complete the image of three-dimensional (3D) innervation in lung cancer. The interaction between peripheral nerves and lung cancer may affect the phenotype of peripheral nerves and thus regulate the malignant biological course of lung cancer. PNS may play an oncogenic role in lung tumor progression and may serve as a therapeutic target for further analysis.
Legal entity responsible for the study
Shanghai Chest Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
126P - Evaluation of Myeloid Targeting Agents, PY159 and PY314, in Two Dose Expansion Phase 1b Trials in Platinum-Resistant Ovarian Cancer
Presenter: Oladapo Yeku
Session: Poster Display
116TiP - Randomized, open-label, phase II study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer
Presenter: Eric Van Cutsem
Session: Poster Display
127P - REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 dose-escalation study
Presenter: Ira Winer
Session: Poster Display
128P - A phase I dose escalation and expansion trial of LYT-200, a Galectin-9 antibody +/- tislelizumab
Presenter: Gerald Falchook
Session: Poster Display
129P - Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score
Presenter: Brian Kushner
Session: Poster Display
131P - Safety and clinical efficacy of Roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_)
Presenter: Anna Di Giacomo
Session: Poster Display
132P - A phase I clinical trial of QLS31905 in advanced solid tumors
Presenter: Yakun Wang
Session: Poster Display
133P - Phase 1/2 study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Presenter: Diwakar Davar
Session: Poster Display
134P - A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor INCB099318 in Select Advanced Solid Tumors
Presenter: David Pinato
Session: Poster Display
135P - Isunakinra as Monotherapy and Combined with Nivolumab for Treatment Resistant Advanced Solid Tumours: Exploratory Effect Data, Tolerability, and Pharmacokinetics from a Dose Escalation Trial
Presenter: Carlos Becerra
Session: Poster Display